Study to evaluate intraperitoneal (IP) ONCOS-102 with systemic durvalumab in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Phase 2 results-MedSci.cn

Study to evaluate intraperitoneal (IP) ONCOS-102 with systemic durvalumab in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Phase 2 results

Zamarin, D; Odunsi, K; Zsiros, E; Slomovitz, BM; Pimentel, A; Duska, LR; Reilley, M; Nemunaitis, JJ; Hamouda, DM; Patel, H; Segal, NH; Pesci, G; Holland, A; Shohara, L; Schwarzenberger, PO; Ricciardi, T; Macri, MJ; Ryan, A; Jaderberg, ME; Venhaus, RR

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (16):

科室
- - 订阅+
  - 更多科室
工具
服务